After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Shares of DexCom slid after the company reported mixed third-quarter results that included disappointing new patient numbers and lower gross margin guidance. The stock fell 15% to $58.10 and is down ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.